본문 바로가기
KERD
논문KCI 등재

Genomic characteristics of triple negative apocrine carcinoma: a comparison to triple negative breast cancer

남석진|이정언|박연희|이세민|안진석|채병주|Park Sabin|김석원|조은윤|Kim Ji-Yeon|Jung Hae Hyun|Cho Soo Youn|Im Young-Hyuck
생화학분자생물학회 (Korean Society Of Biochemistry And Molecular Biology)|2023.12|Experimental and Molecular Medicine|제55권 |pp. 1451-1461|DOI 10.1038/s12276-023-01030-z

0

조회

0

다운로드

0

인용

0

참고문헌

주제분류생화학

초록

Apocrine carcinoma is a rare breast cancer subtype. As such, the genomic characteristics of apocrine carcinoma with triple negative immunohistochemical results (TNAC), which has been treated as triple negative breast cancer (TNBC), have not been revealed. In this study, we evaluated the genomic characteristics of TNAC compared to TNBC with low Ki-67 (LK-TNBC). In the genetic analysis of 73 TNACs and 32 LK-TNBCs, the most frequently mutated driver gene in TNAC was TP53 (16/56, 28.6%), followed by PIK3CA (9/56, 16.1%), ZNF717 (8/56, 14.3%), and PIK3R1 (6/56, 10.71%). Mutational signature analysis showed enrichment of defective DNA mismatch repair (MMR)-related signatures (SBS6 and SBS21) and the SBS5 signature in TNAC, whereas an APOBEC activity-associated mutational signature (SBS13) was more prominent in LK-TNBC (Student’s t test, p < 0.05). In intrinsic subtyping, 38.4% of TNACs were classified as luminal A, 27.4% as luminal B, 26.0% as HER2-enriched (HER2-E), 2.7% as basal, and 5.5% as normal-like. The basal subtype was the most dominant subtype (43.8%) in LK-TNBC (p < 0.001), followed by luminal B (21.9%), HER2-E (21.9%), and luminal A (12.5%). In the survival analysis, TNAC had a five-year disease-free survival (DFS) rate of 92.2% compared to 59.1% for LK-TNBC (P = 0.001) and a five-year overall survival (OS) rate of 95.3% compared to 74.6% for LK-TNBC (P = 0.0099). TNAC has different genetic characteristics and better survival outcomes than LK-TNBC. In particular, normal-like and luminal A subtypes in TNAC have much better DFS and OS than other intrinsic subtypes. Our findings are expected to impact medical practice for patients diagnosed with TNAC.

Abstract

Apocrine carcinoma is a rare breast cancer subtype. As such, the genomic characteristics of apocrine carcinoma with triple negative immunohistochemical results (TNAC), which has been treated as triple negative breast cancer (TNBC), have not been revealed. In this study, we evaluated the genomic characteristics of TNAC compared to TNBC with low Ki-67 (LK-TNBC). In the genetic analysis of 73 TNACs and 32 LK-TNBCs, the most frequently mutated driver gene in TNAC was TP53 (16/56, 28.6%), followed by PIK3CA (9/56, 16.1%), ZNF717 (8/56, 14.3%), and PIK3R1 (6/56, 10.71%). Mutational signature analysis showed enrichment of defective DNA mismatch repair (MMR)-related signatures (SBS6 and SBS21) and the SBS5 signature in TNAC, whereas an APOBEC activity-associated mutational signature (SBS13) was more prominent in LK-TNBC (Student’s t test, p < 0.05). In intrinsic subtyping, 38.4% of TNACs were classified as luminal A, 27.4% as luminal B, 26.0% as HER2-enriched (HER2-E), 2.7% as basal, and 5.5% as normal-like. The basal subtype was the most dominant subtype (43.8%) in LK-TNBC (p < 0.001), followed by luminal B (21.9%), HER2-E (21.9%), and luminal A (12.5%). In the survival analysis, TNAC had a five-year disease-free survival (DFS) rate of 92.2% compared to 59.1% for LK-TNBC (P = 0.001) and a five-year overall survival (OS) rate of 95.3% compared to 74.6% for LK-TNBC (P = 0.0099). TNAC has different genetic characteristics and better survival outcomes than LK-TNBC. In particular, normal-like and luminal A subtypes in TNAC have much better DFS and OS than other intrinsic subtypes. Our findings are expected to impact medical practice for patients diagnosed with TNAC.

참고문헌 (60)

  1. Vranic, S., "Apocrine carcinoma of the breast : a comprehensive review", Histol. Histopathol, 28, pp.1393~1409 (2013)
  2. Ogiya, A., "Apocrine metaplasia of breast cancer : clinicopathological features and predicting response", Breast Cancer, 17, pp.290~297 (2010)
  3. Tsutsumi, Y., "Apocrine carcinoma as triple-negative breast cancer : novel definition of apocrine-type carcinoma as estrogen", progesterone receptor-negative and androgen receptor-positive invasive ductal carcinoma, 2012, pp.42, 375~386
  4. Rakha, E. A., "Basal-like breast cancer : a critical review", J. Clin. Oncol, 26, pp.2568~2581 (2008)
  5. Cancer Genome Atlas, N., "Comprehensive molecular portraits of human breast tumours", Nature, 490, pp.61~70 (2012)
  6. Perou, C. M., "Molecular portraits of human breast tumours", Nature, 406, pp.747~752 (2000)
  7. Foulkes, W. D., "Triple-negative breast cancer", N. Engl J. Med, 363, pp.1938~1948 (2010)
  8. Kumar, P., "An overview of triple-negative breast cancer", Arch. Gynecol. Obstet, 293, pp.247~269 (2016)
  9. Cao, L., "Triple negative breast cancer : special histological types and emerging therapeutic methods", Cancer Biol. Med, 17, pp.293~306 (2020)
  10. Vranic, S., "Immunohistochemical and molecular profiling of histologically defined apocrine carcinomas of the breast", Hum. Pathol, 46, pp.1350~1359 (2015)
  11. Trapani, D., "Benefit of adjuvant chemotherapy in patients with special histology subtypes of triple-negative breast cancer : a systematic review", Breast Cancer Res. Treat, 187, pp.323~337 (2021)
  12. Leon-Ferre, R. A., "Impact of histopathology, tumor-infiltrating lymphocytes, and adjuvant chemotherapy on prognosis of triple-negative breast cancer", Breast Cancer Res. Treat, 167, pp.89~99 (2018)
  13. Thike, A. A., "Loss of androgen receptor expression predicts early recurrence in triple-negative and basal-like breast cancer", Mod. Pathol, 27, pp.352~360 (2014)
  14. Li, H., "Fast and accurate short read alignment with Burrows-Wheeler transform", Bioinformatics, 25, pp.1754~1760 (2009)
  15. DePristo, M. A., "A framework for variation discovery and genotyping using next-generation DNA sequencing data", Nat. Genet, 43, pp.491~498 (2011)
  16. Cibulskis, K., "Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples", Nat. Biotechnol, 31, pp.213~219 (2013)
  17. Fortunato, A., "A new method to accurately identify single nucleotide variants using small FFPE breast samples", Brief Bioinform, 22 (2021)[DOI]
  18. Martincorena, I., "Universal patterns of selection in cancer and somatic tissues", Cell, 173, pp.1823~ (2018)
  19. Rosenthal, R., "DeconstructSigs : delineating mutational processes in single tumors distinguishes DNA repair deficiencies and patterns of carcinoma evolution", Genome Biol, 17, pp.31~ (2016)
  20. Mermel, C. H., "GISTIC2.0 facilitates sensitive and confident localization of the targets of focal somatic copy-number alteration in human cancers", Genome Biol, 12, pp.R41~ (2011)
  21. Zhang, Y., "ComBat-seq: batch effect adjustment for RNA-seq count data", NAR Genom. Bioinform, 2, pp.lqaa078~ (2020)
  22. Johnson, W. E., "Adjusting batch effects in microarray expression data using empirical Bayes methods", Biostatistics, 8, pp.118~127 (2007)
  23. Gendoo, D. M., "Genefu : an R", Bioconductor package for computation of gene expression-based signatures in breast cancer, 2016, pp.32, 1097~1099
  24. Lehmann, B. D., "Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies", J. Clin. Invest, 121, pp.2750~2767 (2011)
  25. Chen, X., "TNBCtype : a subtyping tool for triple-negative breast cancer", Cancer Inform, 11, pp.147~156 (2012)
  26. Burstein, M. D., "Comprehensive genomic analysis identifies novel subtypes and targets of triple-negative breast cancer", Clin. Cancer Res, 21, pp.1688~1698 (2015)
  27. Liu, Y. R., "Comprehensive transcriptome analysis identifies novel molecular subtypes and subtype-specific RNAs of triple-negative breast cancer", Breast Cancer Res, 18, pp.33~ (2016)
  28. Jiang, Y. Z., "Genomic and transcriptomic landscape of triple-negative breast cancers : subtypes and treatment strategies", Cancer Cell, 35, pp.428~440 (2019)
  29. Subramanian, A., "Gene set enrichment analysis : a knowledge-based approach for interpreting genome-wide expression profiles", Proc. Natl Acad. Sci. USA, 102, pp.15545~15550 (2005)
  30. Tarazona, S., "Data quality aware analysis of differential expression in RNAseq with NOISeq R", Bioc package, 2015, pp.43, e140~
  31. Chen, E. Y., "Enrichr : interactive and collaborative HTML5 gene list enrichment analysis tool", BMC Bioinformatics, 14, pp.128~ (2013)
  32. Wu, S. Z., "A single-cell and spatially resolved atlas of human breast cancers", Nat. Genet, 53, pp.1334~1347 (2021)
  33. Newman, A. M., "Determining cell type abundance and expression from bulk tissues with digital cytometry", Nat. Biotechnol, 37, pp.773~782 (2019)
  34. Wang, X., "Bulk tissue cell type deconvolution with multi-subject single-cell expression reference", Nat. Commun, 10, pp.380~ (2019)
  35. Jew, B., "Accurate estimation of cell composition in bulk expression through robust integration of single-cell information", Nat. Commun, 11, pp.1971~ (2020)
  36. Uhrig, S., "Accurate and efficient detection of gene fusions from RNA sequencing data", Genome Res, 31, pp.448~460 (2021)
  37. Jeon, S., "Korean Genome Project: 1094 Korean personal genomes with clinical information", Sci. Adv, 6, pp.eaaz7835~ (2020)
  38. Weisman, P. S., "Genetic alterations of triple negative breast cancer by targeted next-generation sequencing and correlation with tumor morphology", Mod. Pathol, 29, pp.476~488 (2016)
  39. Sun, X., "Invasive apocrine carcinoma of the breast : clinicopathologic features and comprehensive genomic profiling of 18 pure triple-negative apocrine carcinomas", Mod. Pathol, 33, pp.2473~2482 (2020)
  40. Chen, L., "Characterization of PIK3CA and PIK3R1 somatic mutations in Chinese breast cancer patients", Nat. Commun, 9, pp.1357~ (2018)
  41. Barroso-Sousa, R., "Prevalence and mutational determinants of high tumor mutation burden in breast cancer", Ann. Oncol, 31, pp.387~394 (2020)
  42. Nielsen, T. O., "A comparison of PAM50 intrinsic subtyping with immunohistochemistry and clinical prognostic factors in tamoxifen-treated estrogen receptor-positive breast cancer", Clin Cancer Res, 16, pp.5222~5232 (2010)
  43. Khramtsov, A. I., "Wnt", beta-catenin pathway activation is enriched in basallike breast cancers and predicts poor outcome, 2010, pp.176, 2911~2920
  44. Gromov, P., "FABP7 and HMGCS2 are novel protein markers for apocrine differentiation categorizing apocrine carcinoma of the breast", PLoS One, 9, pp.e112024~ (2014)
  45. Vranic, S., "An update on the molecular and clinical characteristics of apocrine carcinoma of the breast", Clin. Breast Cancer (2021)[DOI]
  46. Oshi, M., "The E2F pathway score as a predictive biomarker of response to neoadjuvant therapy in ER+", HER2-breast cancer, 2020, pp.9, ~
  47. Nik-Zainal, S., "Landscape of somatic mutations in 560 breast cancer wholegenome sequences", Nature, 534, pp.47~54 (2016)
  48. Zhu, X., "The prognostic and predictive potential of Ki-67 in triple-negative breast cancer", Sci. Rep, 10, pp.225~ (2020)
  49. Hu, T., "Triple-negative apocrine breast carcinoma has better prognosis despite poor response to neoadjuvant chemotherapy", J. Clin. Med, 11 (2022)[DOI]
  50. Alexandrov, L. B., "The repertoire of mutational signatures in human cancer", Nature, 578, pp.94~101 (2020)
  51. Andre, T., "Pembrolizumab in microsatellite-instability-high advanced colorectal cancer", N. Engl J. Med, 383, pp.2207~2218 (2020)
  52. Binnewies, M., "Understanding the tumor immune microenvironment(TIME)for effective therapy", Nat. Med, 24, pp.541~550 (2018)
  53. Shah, M., "FDA approval summary : pembrolizumab for neoadjuvant and adjuvant treatment of patients with high-risk early-stage triple-negative breast cancer", Clin. Cancer Res, 28, pp.5249~5253 (2022)
  54. Cortes, J., "Pembrolizumab plus chemotherapy in advanced triple-negative breast cancer", N. Engl J. Med, 387, pp.217~226 (2022)
  55. Loi, S., "The journey of tumor-infiltrating lymphocytes as a biomarker in breast cancer : clinical utility in an era of checkpoint inhibition", Ann. Oncol, 32, pp.1236~1244 (2021)
  56. Tay, R. E., "Revisiting the role of CD4(+)T cells in cancer immunotherapy-new insights into old paradigms", Cancer Gene Ther, 28, pp.5~17 (2021)
  57. Carey, L. A., "Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study", JAMA, 295, pp.2492~2502 (2006)
  58. Cardoso, F., "70-gene signature as an aid to treatment decisions in early-stage breast cancer", N. Engl J. Med, 375, pp.717~729 (2016)
  59. Cardoso, F., "Early breast cancer : ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-updagger", Ann. Oncol, 30, pp.1194~1220 (2019)
  60. Sparano, J. A., "Weekly paclitaxel in the adjuvant treatment of breast cancer", N. Engl J. Med, 358, pp.1663~1671 (2008)

관련 논문AI추천

Association between Mutation and Expression of TP53 as a Potential Prognostic Marker of Triple-Negative Breast Cancer김석원, 김지연, 남석진, 박경희, 박연희, 배수연, 안진석, 이광희, 이세경, 이은진, 이정언, 임영혁, 정혜현, 조은윤대한암학회 · Cancer Research and Treatment2016 · 제48권 제4호Genomic Signatures from Clinical Tumor Sequencing in Patients with Breast Cancer Having Germline BRCA1/2 Mutation강효은, 김열홍, 김주원, 박경화, 배수연, 유지영, 윤승규, 정승필, 최윤지, 최지미대한암학회 · Cancer Research and Treatment2023 · 제55권 제1호PIK3CA Mutation Is Associated with Poor Response to HER2-Targeted Therapy in Breast Cancer Patients김주원, 김철용, 박경화, 송성은, 유지영, 이남권, 이정현, 임아름, 정승필, 조규란대한암학회 · Cancer Research and Treatment2023 · 제55권 제2호Treatment Approach for Rare Histologic Subtypes of Breast Cancer: A ReviewJung Sung Ui한국유방암학회 · Journal of Breast Disease2024 · 제12권 제2호Discordance of the PAM50 Intrinsic Subtypes Compared with Immunohistochemistry-Based Surrogate in Breast Cancer Patients: Potential Implication of Genomic Alterations of Discordance김유진, 김지연, 김희경, 박경희, 박송이, 박연희, 안진석, 유종한, 이정언, 이한상, 임성원, 임영혁, 조장호대한암학회 · Cancer Research and Treatment2019 · 제51권 제2호The Clinicopathologic Features of Molecular Apocrine Breast Cancer구자승, 정우희, 차윤진대한병리학회 · Journal of Pathology and Translational Medicine2012 · 제46권 제2호

이 간행물의 다른 논문 (225건)

Endothelial senescence in vascular diseases: current understanding and future opportunities in senotherapeutics김성영, Han Yeaeunpp. 1-12Grave-to-cradle: human embryonic lineage tracing from the postmortem bodyKu Eu Jeong, Choi Seock Hwan, Choi Yujin Angelina, Oh Ji Wonpp. 13-21Chromatin and noncoding RNA-mediated mechanisms of gastric tumorigenesisKim Tae-Hee, Loe Adrian Kwan Ho, Zhu Lexinpp. 22-31TPX2 prompts mitotic survival via the induction of BCL2L1 through YAP1 protein stabilization in human embryonic stem cellsCha Hyuk-Jin, Kim Yun-Jeong, Go Young-Hyun, 정호창, Kwon Eun-Ji, Kim Seong-Min, Cheong Hyun Sub, Kim Wantae, Shin Hyoung Doo, Lee Haeseungpp. 32-42ZBTB7A suppresses glioblastoma tumorigenesis through the transcriptional repression of EPB41L5Nam Hae Yun, 김성학, 김승후, 최경철, Park Seung-Ho, Song Ji-Hye, Jeong Ji-Hoon, Kim Hyunhee, Jeong Minseok, Kong Min-Jeong, Son Jihyun, Jeong Ji-Eunpp. 43-54
원문 보기